A citation-based method for searching scientific literature

Luisa Maresca, Barbara Stecca, Laura Carrassa. Cells 2022
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting apoptosis in cancer therapy.
Benedito A Carneiro, Wafik S El-Deiry. Nat Rev Clin Oncol 2020
494
100

Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
Vladimir N Ivanov, Hongning Zhou, Michael A Partridge, Tom K Hei. Cancer Res 2009
48
50

Type I interferons in anticancer immunity.
Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp, Mark J Smyth, Guido Kroemer. Nat Rev Immunol 2015
646
50

Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.
Pierpaola Davalli, Gaetano Marverti, Angela Lauriola, Domenico D'Arca. Oxid Med Cell Longev 2018
59
50


The good and the bad faces of STAT1 in solid tumours.
Katrin Meissl, Sabine Macho-Maschler, Mathias Müller, Birgit Strobl. Cytokine 2017
152
50

Mechanisms of PARP inhibitor sensitivity and resistance.
Alan D D'Andrea. DNA Repair (Amst) 2018
209
50

PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M Sholl, Keith M Kerr, Sacha Gnjatic, Ignacio I Wistuba, David L Rimm, Ming Sound Tsao, Fred R Hirsch. Nat Rev Clin Oncol 2021
221
50

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.
Niklas Finnberg, Andres J P Klein-Szanto, Wafik S El-Deiry. J Clin Invest 2008
139
50

Role of macrophage targeting in the antitumor activity of trabectedin.
Giovanni Germano, Roberta Frapolli, Cristina Belgiovine, Achille Anselmo, Samantha Pesce, Manuela Liguori, Eugenio Erba, Sarah Uboldi, Massimo Zucchetti, Fabio Pasqualini,[...]. Cancer Cell 2013
553
50

WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway.
Ensong Guo, Rourou Xiao, Yifan Wu, Funian Lu, Chen Liu, Bin Yang, Xi Li, Yu Fu, Zizhuo Wang, Yuan Li,[...]. J Exp Med 2022
5
50

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.
Erika Cretney, Kazuyoshi Takeda, Hideo Yagita, Moira Glaccum, Jacques J Peschon, Mark J Smyth. J Immunol 2002
495
50

Role of DNA repair defects in predicting immunotherapy response.
Jing Zhang, David J H Shih, Shiaw-Yih Lin. Biomark Res 2020
29
50

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.
Zongren Wang, Xueling Zhang, Wuguo Li, Qiao Su, Zhaoyang Huang, Xinyao Zhang, Haiqi Chen, Chengqiang Mo, Bin Huang, Wei Ou,[...]. J Immunother Cancer 2021
4
50

Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers.
Martina Mang Leng Lei, Terence Kin Wah Lee. Front Cell Dev Biol 2021
21
50

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Eric Haines, Yuki Nishida, Michael I Carr, Rafael Heinz Montoya, Lauren B Ostermann, Weiguo Zhang, Frank T Zenke, Andree Blaukat, Michael Andreeff, Lyubomir T Vassilev. Sci Rep 2021
7
50

Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production.
Hiroyasu Konno, Shota Yamauchi, Anders Berglund, Ryan M Putney, James J Mulé, Glen N Barber. Oncogene 2018
96
50



A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.
A Younes, J M Vose, A D Zelenetz, M R Smith, H A Burris, S M Ansell, J Klein, W Halpern, R Miceli, E Kumm,[...]. Br J Cancer 2010
105
50

Type I interferon: a new player in TNF signaling.
Anna Yarilina, Lionel B Ivashkiv. Curr Dir Autoimmun 2010
40
50

Genomic alterations and abnormal expression of APE2 in multiple cancers.
Katherine A Jensen, Xinghua Shi, Shan Yan. Sci Rep 2020
15
50

WEE1 Inhibitor: Clinical Development.
Anthony Kong, Hisham Mehanna. Curr Oncol Rep 2021
10
50


Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Win Topatana, Sarun Juengpanich, Shijie Li, Jiasheng Cao, Jiahao Hu, Jiyoung Lee, Kenneth Suliyanto, Diana Ma, Bin Zhang, Mingyu Chen,[...]. J Hematol Oncol 2020
41
50

Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer.
Lukas Gorecki, Martin Andrs, Jan Korabecny. Cancers (Basel) 2021
25
50

TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death.
Yoshie Miura, Takayuki Tsujioka, Yasumitsu Nishimura, Haruko Sakaguchi, Megumi Maeda, Hiroaki Hayashi, Maolong Dong, Fuminori Hyodoh, Ken-Ichiro Yata, Hideho Wada,[...]. Anticancer Res 2006
28
50

cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers.
Christy Hong, Michael Schubert, Andréa E Tijhuis, Marta Requesens, Maurits Roorda, Anouk van den Brink, Lorena Andrade Ruiz, Petra L Bakker, Tineke van der Sluis, Wietske Pieters,[...]. Nature 2022
12
50


Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
Sweta Sharma Saha, Lucy Gentles, Alice Bradbury, Dominik Brecht, Rebecca Robinson, Rachel O'Donnell, Nicola J Curtin, Yvette Drew. Cancers (Basel) 2021
4
50

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Eliezer M Van Allen, Kent W Mouw, Philip Kim, Gopa Iyer, Nikhil Wagle, Hikmat Al-Ahmadie, Cong Zhu, Irina Ostrovnaya, Gregory V Kryukov, Kevin W O'Connor,[...]. Cancer Discov 2014
370
50


DNA damage response and resistance of cancer stem cells.
Etna Abad, Dmitry Graifer, Alex Lyakhovich. Cancer Lett 2020
48
50

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
Thomas Condamine, Vinit Kumar, Indu R Ramachandran, Je-In Youn, Esteban Celis, Niklas Finnberg, Wafik S El-Deiry, Rafael Winograd, Robert H Vonderheide, Nickolas R English,[...]. J Clin Invest 2014
219
50

Clinically Applicable Inhibitors Impacting Genome Stability.
Anu Prakash, Juan F Garcia-Moreno, James A L Brown, Emer Bourke. Molecules 2018
13
50


Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.
N Arbour, E Rastikerdar, E McCrea, Y Lapierre, J Dörr, A Bar-Or, J P Antel. Mult Scler 2005
27
50


A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
Andrea Ghelli Luserna di Rorà, Claudio Cerchione, Giovanni Martinelli, Giorgia Simonetti. J Hematol Oncol 2020
55
50


DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
Hiro Sato, Atsuko Niimi, Takaaki Yasuhara, Tiara Bunga Mayang Permata, Yoshihiko Hagiwara, Mayu Isono, Endang Nuryadi, Ryota Sekine, Takahiro Oike, Sangeeta Kakoti,[...]. Nat Commun 2017
322
50

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Hirokazu Taniguchi, Rebecca Caeser, Shweta S Chavan, Yingqian A Zhan, Andrew Chow, Parvathy Manoj, Fathema Uddin, Hidenori Kitai, Rui Qu, Omar Hayatt,[...]. Cell Rep 2022
3
50

Progress towards a clinically-successful ATR inhibitor for cancer therapy.
Francis M Barnieh, Paul M Loadman, Robert A Falconer. Curr Res Pharmacol Drug Discov 2021
26
50

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Praveen Vikas, Nicholas Borcherding, Adithya Chennamadhavuni, Rohan Garje. Front Oncol 2020
75
50

Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation.
Hann-Hsiang Chao, Ilias V Karagounis, Christoforos Thomas, Noëlle B François, Andrea Facciabene, Constantinos Koumenis, Amit Maity. Oncogene 2020
12
50


PARP inhibitors in ovarian cancer: An overview of the practice-changing trials.
Tiffany Foo, Angela George, Susana Banerjee. Genes Chromosomes Cancer 2021
23
50



PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee,[...]. Clin Cancer Res 2017
503
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.